Navigating NMIBC treatment changes
If you experience audio disruptions, please use the captions feature via the settings (cog icon) in the video player.
Episode 5. Ashish Kamat and Roger Li dissect the clinical complexities of Bacillus Calmette–Guérin (BCG)-unresponsive NMIBC, including how strict trial criteria translate to real-world patient selection, the clinical impact of carcinoma in situ versus papillary disease, and the rise of gemcitabine–docetaxel as a preferred first-line option in academic centers. The discussion reveals why efficacy, toxicity, and cost drive therapy choices, how sustained-release platforms may reshape chemotherapy delivery, and the challenges of guiding increasingly informed patients through data-driven decisions. “We want to choose the most efficacious agent for all of our patients,” concludes Li, underscoring the balance between evidence, experience, and patient-centered care. View transcript.
Chapters
00:37 Managing BCG-unresponsive NMIBC
02:42 Defining BCG-unresponsive disease
07:10 Doublet chemotherapy: Practical insights
11:54 Treatment for patients with CIS
16:49 Sustained-release platforms in NMIBC
18:29 Patient support in therapy choices
Meet the guest speaker
Roger Li, MD
Roger Li is a urologic oncologist at Moffitt Cancer Center, Tampa, Florida, USA, specializing in bladder, upper tract urothelial, and prostate cancer. He leads research on molecular profiling and immunotherapy in urothelial malignancies, with a focus on BCG-unresponsive disease. He has authored over 150 peer-reviewed publications and contributes to multiple international urology journals.
Disclosures: Research funding from American Cancer Society, Bladder Cancer Advocacy Network (BCAN), and US Department of Defense.
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.